SCHEMBL20356643

SCHEMBL20356643

CCNc1nc(C(=O)O)nc(CC)c1Cc1ccccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC26A6 Q9BXS9 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ CD38 P28907 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ PGK1 P00558 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20356647 0.91 SLC26A6 (0.40) SLC26A6SMN1; SMN2LMNAALDH1A1HTT
SCHEMBL21526137 0.86 SMN1; SMN2 (0.41) SMN1; SMN2CD38LMNAHTTHPGD
SCHEMBL20356644 0.84 POLB (0.37) SLC26A6SMN1; SMN2CD38LMNAALDH1A1
SCHEMBL21526001 0.82 SMN1; SMN2 (0.38) SLC26A6SMN1; SMN2LMNARXFP1TDP1
SCHEMBL21548901 0.82 SMN1; SMN2 (0.41) SLC26A6SMN1; SMN2ALDH1A1HTTHSD17B10
SCHEMBL20356705 0.81 MAPT (0.40) SLC26A6SMN1; SMN2ALDH1A1HTTHPGD
Hydrochloric Acid SCHEMBL28322143 0.81 SMN1; SMN2 (0.37) SLC26A6SMN1; SMN2LMNARXFP1TDP1
SCHEMBL20356519 0.79 MAPK8 (0.38) SLC26A6SMN1; SMN2LMNAALDH1A1HTT
Hydrochloric Acid SCHEMBL21526076 0.78 MAPK8 (0.38) SLC26A6SMN1; SMN2LMNAALDH1A1HTT
SCHEMBL20356659 0.77 SMN1; SMN2 (0.36) SLC26A6SMN1; SMN2ALDH1A1TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564216-B1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
EP-3564216-B1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
US-11034659-B2 Pyrimidine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-15 — — US disclosed
US-20200172494-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-06-04 — — US disclosed
EP-3564216-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-11-06 — — EP disclosed
EP-3564216-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-11-06 — — EP disclosed
WO-2018124000-A1 PYRIMIDINE DERIVATIVE 第一三共株式会社 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034659-B2 Pyrimidine derivative GPR39, CFTR, TMEM109 SLC26A6 512/4885SMN1; SMN2 2983/4885CD38 1691/4885
US-20200172494-A1 PYRIMIDINE DERIVATIVE GPR39, CFTR, TMEM109 SLC26A6 512/4885SMN1; SMN2 2983/4885CD38 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback